Nvg-2089

2 trials 1 recruiting

Filter these 2 trials by condition, phase, country and more.

Open in Search →

2 Registered trials

1 Recruiting

1 Completed trials

1 Sponsors

7 Countries

Phase II

Phase II: 2

Oversight events:

1 serious breach 6 temporary halts 1 corrective measure across 1 trial

View oversight register →

Indications tested

Chronic inflammatory demyelinating polyradiculoneuropathy 1

Sponsors using this IMP

Nuvig Therapeutics Inc. 2

All trials

2 total

Safety, Tolerability, and Efficacy of NVG-2089 in Participants with Immune Thrombocytopenia Recruiting

2024-520359-26-00 Phase II 3 countries Nuvig Therapeutics Inc.
Safety, Tolerability, and Efficacy of NVG-2089 in Participants with CIDP Ended

2024-515386-34-00 Phase II 6 countries Nuvig Therapeutics Inc.

Showing 1–2 of 2 trials

← All drugs A–Z